<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600587</url>
  </required_header>
  <id_info>
    <org_study_id>CSLC-0702</org_study_id>
    <secondary_id>tarceva-123456-1</secondary_id>
    <nct_id>NCT00600587</nct_id>
  </id_info>
  <brief_title>Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase Ⅱ Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the value of induction Erlotinib therapy before
      thoracotomy or radiotherapy in ⅢA-N2 (confirmed by mediastinoscopy or PET) non-small cell
      lung cancer (NSCLC) selected by epidermal growth factor receptor (EGFR) gene analysis and
      initial to explore a new treatment strategy for ⅢA-N2 NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage IIIA non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of
      patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of
      different treatment modalities are not clear. Epidermal growth factor receptor (EGFR)
      tyrosine kinase inhibitors (TKIs) may result in dramatic responses in patients with pulmonary
      adenocarcinoma carrying EGFR activating mutations. In case reports, the efficacy of
      perioperative EGFR-TKI therapy in patients with locally advanced NSCLC harboring EGFR gene
      mutations was satisfactory. Although no prospective data support the use of EGFR-TKIs as
      induction therapy in stage IIIA-N2 NSCLC, their low toxicity profile and the possibility of a
      rapid tumor response suggests that prospective trials are required. Therefore, this study
      evaluated the value of induction erlotinib therapy in IIIA-N2 NSCLC selected by EGFR gene
      analysis and explored a new treatment strategy for this subset. Erlotinib specifically
      targets the EGFR TK domain, which is highly expressed and occasionally mutated in various
      forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding
      site of the receptor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Neoadjuvant Erlotinib Therapy</measure>
    <time_frame>a week after completion of the induction erlotinib therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete resection rate</measure>
    <time_frame>7 days after thoractomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Neoadjuvant Erlotinib Therapy and postoperative complications</measure>
    <time_frame>one months after thoractomy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-erlotinib targeted NSCLC population based on EGFR gene analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant erlotinib therapy</intervention_name>
    <description>150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant gemcitabine/carboplatin therapy</intervention_name>
    <description>3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histological or cytological documented

          -  Resectable NSCLC of stage IIIA-N2 confirmed by mediastinoscopy or PET

          -  Naive therapy NSCLC

          -  Candidates should be tolerated with induction therapy and thoracotomy with ECOG
             performance status 0-2, adequate haematological and Hepatic- renal function and
             qualified lung function

          -  Enough tissue samples to perform gene analysis

        Exclusion Criteria:

          -  Small cell lung cancer

          -  Pregnant or breast-feeding women

          -  Any unstable systemic disease

          -  Patients with exposure to investigational drug therapy or other concurrent anticancer
             therapy outside of this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-long WU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xue-ning YANG, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wen-zhao ZHONG, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007 May;2(5):430-9.</citation>
    <PMID>17473659</PMID>
  </reference>
  <reference>
    <citation>Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct;58(1):95-103. Epub 2007 Jul 3.</citation>
    <PMID>17610986</PMID>
  </reference>
  <reference>
    <citation>Takamochi K, Suzuki K, Sugimura H, Funai K, Mori H, Bashar AH, Kazui T. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer. 2007 Oct;58(1):149-55. Epub 2007 Jun 4.</citation>
    <PMID>17548126</PMID>
  </reference>
  <reference>
    <citation>Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. J Clin Oncol. 2008 Sep 1;26(25):4205-7. doi: 10.1200/JCO.2008.16.3709.</citation>
    <PMID>18757336</PMID>
  </reference>
  <reference>
    <citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.</citation>
    <PMID>19692680</PMID>
  </reference>
  <reference>
    <citation>Robinson LA, Wagner H Jr, Ruckdeschel JC; American College of Chest Physicians. Treatment of stage IIIA non-small cell lung cancer. Chest. 2003 Jan;123(1 Suppl):202S-220S. Review.</citation>
    <PMID>12527580</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>June 23, 2013</last_update_submitted>
  <last_update_submitted_qc>June 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong General Hospital</investigator_affiliation>
    <investigator_full_name>Wen-zhao ZHONG</investigator_full_name>
    <investigator_title>Guangdong General Hospital</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Genes, erbB-1</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

